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Background
Previously, we reported that there was no significant difference at 30 days in the rate 
of a primary composite outcome of death, myocardial infarction, stroke, or new 
renal failure requiring dialysis between patients who underwent coronary-artery 
bypass grafting (CABG) performed with a beating-heart technique (off-pump) and 
those who underwent CABG performed with cardiopulmonary bypass (on-pump). We 
now report results on quality of life and cognitive function and on clinical outcomes 
at 1 year.
Methods
We enrolled 4752 patients with coronary artery disease who were scheduled to un-
dergo CABG and randomly assigned them to undergo the procedure off-pump or 
on-pump. Patients were enrolled at 79 centers in 19 countries. We assessed quality 
of life and cognitive function at discharge, at 30 days, and at 1 year and clinical 
outcomes at 1 year.
Results
At 1 year, there was no significant difference in the rate of the primary composite 
outcome between off-pump and on-pump CABG (12.1% and 13.3%, respectively; 
hazard ratio with off-pump CABG, 0.91; 95% confidence interval [CI], 0.77 to 1.07; 
P = 0.24). The rate of the primary outcome was also similar in the two groups in the 
period between 31 days and 1 year (hazard ratio, 0.79; 95% CI, 0.55 to 1.13; P = 0.19). 
The rate of repeat coronary revascularization at 1 year was 1.4% in the off-pump 
group and 0.8% in the on-pump group (hazard ratio, 1.66; 95% CI, 0.95 to 2.89; 
P = 0.07). There were no significant differences between the two groups at 1 year in 
measures of quality of life or neurocognitive function.
Conclusions
At 1 year after CABG, there was no significant difference between off-pump and 
on-pump CABG with respect to the primary composite outcome, the rate of repeat 
coronary revascularization, quality of life, or neurocognitive function. (Funded by the 
Canadian Institutes of Health Research; CORONARY ClinicalTrials.gov number, 
NCT00463294.)
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Coronary-artery bypass grafting (CABG) reduces mortality among patients with extensive coronary artery disease.1 
CABG is usually performed with the use of car-
diopulmonary bypass (on-pump CABG). With this 
approach, perioperative mortality is about 2%, and 
myocardial infarction, stroke, or renal failure re-
quiring dialysis develop in an additional 5 to 7% 
of patients. The technique of performing CABG 
on a beating heart (off-pump CABG) was devel-
oped to reduce perioperative complications, some 
of which may be related to the use of cardiopul-
monary bypass and to the cross-clamping of the 
aorta associated with the on-pump CABG proce-
dure, and to improve long-term outcomes.
A number of trials have compared off-pump 
CABG with on-pump CABG.2-6 Among the larg-
est trials are the Randomized On/Off Bypass 
(ROOBY)7,8 trial, which enrolled 2203 patients 
from the Veterans Affairs medical system, and the 
Danish On-Pump versus Off-Pump Randomization 
Study (DOORS), which enrolled 900 patients.9,10 
Neither of these trials had sufficient power to 
accurately assess moderate but clinically impor-
tant differences between the groups with respect 
to death, myocardial infarction, stroke, or renal 
failure. As shown in a number of smaller tri-
als,11-14 the skills of the participating surgeons 
can influence the outcome of a specific surgical 
procedure, and the level of surgical expertise 
required by the protocol, particularly for the off-
pump procedure, varied among these trials.
To evaluate the effects of off-pump CABG as 
compared with on-pump CABG, we conducted a 
large, international trial — the CABG Off or On 
Pump Revascularization Study (CORONARY) — in 
which 4752 patients were enrolled. To overcome 
some of the limitations of prior trials, we con-
ducted the trial at a wider range of hospital types 
than those in the previous trials and included 
only experienced surgeons. Previously we report-
ed the 30-day outcomes of the trial.15 The rate of 
the primary outcome (a composite of death, myo-
cardial infarction, stroke, or new renal failure re-
quiring dialysis) was similar in the two groups at 
30 days. The rate of repeat revascularization (per-
cutaneous coronary intervention [PCI] or CABG) 
early after CABG (<30 days after randomization) 
was higher in the off-pump group. The rates of 
bleeding, acute kidney injury, and respiratory 
complications were lower with off-pump CABG 
than with on-pump CABG.
Similar to the results of CORONARY, the re-
sults of the ROOBY trial showed no significant 
difference in the 30-day primary outcome; in the 
ROOBY trial, however, the rate of the primary com-
posite outcome at 1 year (death from any cause, 
repeat revascularization, or nonfatal myocardial 
infarction) was higher with off-pump CABG than 
with on-pump CABG. Because the 1-year results 
in the ROOBY trial have raised concern about the 
value of off-pump surgery, we report the 1-year 
results in CORONARY.
ME THODS
Trial Design
CORONARY was a randomized, controlled trial, 
with blinded adjudication of outcomes, that com-
pared off-pump CABG with on-pump CABG 
among patients undergoing isolated CABG. The 
primary hypothesis was that the rate of major 
clinical events would be lower with off-pump 
CABG than with on-pump CABG in the short 
term (30 days) and that the benefits would be 
maintained in the long term (5 years). The study 
protocol has been published previously16 and is 
also available with the full text of this article at 
NEJM.org. The 30-day results have also been 
published previously.15
The trial was designed by the authors and ap-
proved by national regulatory authorities and by 
the ethics committee at each participating cen-
ter. The data were gathered and analyzed by the 
Population Health Research Institute (McMaster 
University, Hamilton, Ontario, Canada). All the 
authors vouch for the accuracy and completeness 
of the data and analyses and for the fidelity of 
this report to the trial protocol.
Patients
Patients who were scheduled to undergo CABG 
were eligible to participate in the trial if they re-
quired isolated CABG with median sternotomy 
and had one or more of the following risk fac-
tors: an age of 70 years or more, peripheral arte-
rial disease, cerebrovascular disease or carotid 
stenosis of 70% or more of the luminal diameter, 
or renal insufficiency. Patients 60 to 69 years of 
age were eligible if they had at least one of the 
following risk factors: diabetes requiring treat-
ment with an oral hypoglycemic agent or insulin, 
the need for urgent revascularization after an 
acute coronary syndrome, a left ventricular ejec-
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tion fraction of 35% or less, or a recent history of 
smoking (<1 year before randomization); patients 
55 to 59 years of age were eligible if they had at 
least two of those risk factors. All patients were 
required to provide written informed consent.
Qualification of Surgeons
To ensure that surgeons were skilled in the tech-
nique assigned, we used the approach of an exper-
tise-based, randomized, controlled trial.17 Each 
procedure was performed by a surgeon with ex-
pertise in the specific type of surgery that the 
patient was assigned to undergo. A surgeon was 
considered to have expertise if he or she had more 
than 2 years of experience after residency train-
ing and had completed more than 100 cases of the 
specific technique (either on-pump or off-pump 
CABG). Surgeons who met these criteria for each 
type of operation separately were considered to 
have expertise in both techniques and were al-
lowed to perform both types of CABG surgery 
during the trial. Trainees were not allowed to be 
the primary surgeon.
Trial Outcomes
The trial included two coprimary outcomes. The 
first was a composite rate of death, nonfatal 
stroke, nonfatal myocardial infarction, or nonfa-
tal new renal failure requiring dialysis at 30 days 
after randomization. This outcome was also as-
sessed at 1 year. The second coprimary outcome 
consisted of the first coprimary outcome plus the 
rate of repeat coronary revascularization at a 
mean of 5 years. All deaths in the first 30 days 
were considered to be cardiovascular-related deaths. 
All reported events of the components of the pri-
mary outcome and of recurrent angina were re-
viewed by an adjudication committee whose mem-
bers were unaware of the group assignments. 
The outcome events as adjudicated by that com-
mittee were included in the statistical analyses.
We used the European Quality of Life–5 Dimen-
sions questionnaire (EQ-5D)18,19 and the EQ-5D 
visual-analogue scale to assess the quality of life. 
The EQ-5D score ranges from 0 to 1, with higher 
scores indicating a better quality of life. The EQ-5D 
visual-analogue scale ranges from 0 to 100, with 
higher scores indicating a better quality of life.
To assess neurocognitive function, we followed 
the guidelines on vascular cognitive impairment 
harmonization standards from the joint National 
Institute of Neurological Disorders and Stroke–
Canadian Stroke Network (NINDS-CSN).20 We 
used three neurocognitive tests: the Montreal Cog-
nitive Assessment,21 the Digit Symbol Substitution 
Test,22,23 and the Trail Making Test Part B.24-26 
Scores on the Montreal Cognitive Assessment 
range from 0 to 30, with higher scores indicating 
better cognitive function. The lowest score on 
the Digit Symbol Substitution Test is 0 and there 
is no upper limit; higher scores indicate better 
cognitive function. The Trail Making Test Part B 
is a timed test in which a lower score (in sec-
onds) indicates better function.
The quality-of-life and neurocognitive assess-
ments were originally intended to be mandatory 
for all participants but were made optional early 
in the course of the trial to improve recruitment. 
The decision about a patient’s participation in 
these assessments was made on an individual 
basis; centers could select for these assessments 
patients who might be more likely to return to 
the hospital during the follow-up period to com-
plete the tests. The decision to participate was 
made before randomization, to avoid biases. All 
the quality-of-life and neurocognitive tests were 
administered before CABG was performed (be-
fore randomization), at the time of discharge, at 
30 days, and at 1 year.
Statistical Analysis
All analyses were conducted according to the in-
tention-to-treat principle. After testing the as-
sumption of proportional hazards, we conducted 
a time-to-event analysis, using Cox regression to 
report the 1-year outcomes. The time to the first 
occurrence of any one of the components of the 
primary outcome was described with the use of 
Kaplan–Meier survival curves, and the compari-
sons between the two study groups were per-
formed with the use of a log-rank test. The treat-
ment effect is expressed as the hazard ratio (with 
95% confidence intervals), which was derived 
from the Cox proportional-hazards model for the 
first coprimary outcome at 1 year. The comparison 
between the two operative techniques was assessed 
in subgroups defined according to the presence or 
absence of diabetes, the presence or absence of 
cerebrovascular disease, left ventricular function, 
the number of diseased vessels, sex, age, body-
mass index, region, and European System for 
Cardiac Operative Risk Evaluation (EuroSCORE) 
grade, and tests for interaction were performed 
with the use of a Cox proportional-hazards model. 
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We also conducted landmark analyses assessing 
these outcomes between 31 days and 1 year; in 
these analyses, data from patients who had a pri-
mary outcome in the first 30 days or who were 
not followed up after 30 days were not included.
To analyze the quality-of-life and neurocogni-
tive data at each follow-up point (i.e., hospital 
discharge, 30 days, and 1 year), we calculated the 
changes in assessment scores from baseline to 
the follow-up point for each patient, limiting the 
analysis to patients for whom data were available 
both at baseline and at the follow-up point being 
analyzed. The mean value for the change in score 
was then calculated within each group,27 and these 
means were compared between the two groups.
R ESULT S
Patients
From November 2006 through October 2011, a 
total of 4752 patients were enrolled at 79 hospi-
tals in 19 countries and were randomly assigned 
to undergo either off-pump CABG (2375 patients) 
or on-pump CABG (2377 patients). The baseline 
characteristics of the overall trial population have 
been reported previously and are also provided in 
Table S1 in the Supplementary Appendix, avail-
able at NEJM.org. One-year follow-up data on the 
clinical outcomes were available for 98.7% of the 
patients.
Primary and Other Clinical Outcomes
At 1 year, a primary outcome event had occurred 
in 288 participants (12.1%) in the off-pump group 
and 316 participants (13.3%) in the on-pump 
group (hazard ratio with the off-pump procedure, 
0.91; 95% confidence interval [CI], 0.77 to 1.07; 
P = 0.24) (Fig. 1 and Table 1). The rates of indi-
vidual components of this composite outcome 
did not differ significantly between the groups. 
No significant interactions were seen between the 
procedure and any of the subgroup variables (Fig. 
2). There were no significant differences between 
the off-pump group and the on-pump group in 
the rates of recurrent angina (1.0% and 0.9%, 
respectively) or in the need for repeat revascular-
ization by means of PCI or CABG (1.4% [33 pa-
tients] and 0.8% [20 patients], respectively; haz-
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Figure 1. Kaplan–Meier Curves for the Primary Composite Outcome at 1 Year.
The primary outcome was the composite of death, nonfatal myocardial infarction, nonfatal stroke, or nonfatal new 
renal failure requiring dialysis. The inset shows the same data on an enlarged y axis.
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ard ratio, 1.66; 95% CI, 0.95 to 2.89; P = 0.07). 
The rate of the primary outcome among patients 
who underwent the assigned procedure (i.e., with-
out crossing over to the other procedure) was 
similar to the rate in the intention-to-treat popu-
lation (11.5% in the off-pump group and 13.2% 
in the on-pump group; hazard ratio, 0.86; 95% 
CI, 0.73 to 1.02; P = 0.08).
The landmark analysis for the period between 
31 days and 1 year showed a similar risk of the 
primary outcome in the two groups: 55 of the 
2142 patients in the off-pump group included in 
this analysis (2.6%) and 69 of the 2130 patients 
in the on-pump group included in this analysis 
(3.2%) had a primary outcome event (hazard ra-
tio, 0.79; 95% CI, 0.55 to 1.13; P = 0.19) (Table 2). 
These landmark analyses also showed that the 
rates of recurrent angina and repeat revascular-
ization by means of PCI or CABG were similar in 
the on-pump and off-pump groups for the period 
between 31 days and 1 year (recurrent angina: 
0.8% and 0.7%, respectively; hazard ratio, 1.13; 
95% CI, 0.56 to 2.26; P = 0.74; and repeat revas-
cularization: 0.7% and 0.6%, respectively; hazard 
ratio, 1.22; 95% CI, 0.59 to 2.54; P = 0.59).
Quality-of-Life and Neurocognitive 
Outcomes
A total of 2850 patients initially agreed to pro-
vide data for the substudies of quality of life and 
neurocognitive function (Table S1 in the Supple-
mentary Appendix). However, some of these pa-
tients did not provide data for one or more of the 
substudy tests at the various follow-up points 
(Table 3, and Table S2 in the Supplementary Ap-
pendix). The rates of the primary outcome were 
lower among patients who agreed to participate 
in the substudies than among those who did not, 
but there was no interaction between substudy 
participation and group assignment with respect 
to the primary outcome (Table S3 in the Supple-
mentary Appendix). There was a small decline in 
quality of life, as measured by the EQ-5D, in both 
groups at the time of discharge (Table 3), but this 
was followed by a sharp increase in perceived 
quality of life by patients in both groups at 30 
days and at 1 year after surgery. There was no 
significant difference between the two groups in 
quality-of-life scores at any time point. There was 
less reduction from baseline in neurocognitive 
function, as assessed with the use of the Digit 
Table 1. Outcomes at 1 Year.*
Outcome
Off-Pump CABG  
(N = 2375)
On-Pump CABG
(N = 2377)
Hazard Ratio
(95% CI) P Value
Primary outcome — no. (%)† 288 (12.1) 316 (13.3) 0.91 (0.77–1.07) 0.24
Components of primary outcome — no. (%)
Death 122 (5.1) 119 (5.0) 1.03 (0.80–1.32)
Myocardial infarction 161 (6.8) 178 (7.5) 0.90 (0.73–1.12)
Stroke 36 (1.5) 40 (1.7) 0.90 (0.57–1.41)
New renal failure requiring dialysis 30 (1.3) 31 (1.3) 0.97 (0.59–1.60)
Other prespecified outcomes — no. (%)
Cardiovascular-related death‡ 99 (4.2) 96 (4.0) 1.03 (0.78–1.37) 0.83
Angina 23 (1.0) 22 (0.9) 1.05 (0.58–1.88) 0.87
Other outcomes
Repeat revascularization — no. (%)§ 33 (1.4) 20 (0.8) 1.66 (0.95–2.89) 0.07
PCI 27 (1.1) 19 (0.8) 1.43 (0.79–2.57) 0.23
CABG 7 (0.3) 1 (<0.1) 7.00 (0.86–57.0) 0.07
Primary outcome in per protocol population — 
no./total no. (%)
252/2191 (11.5) 295/2227 (13.2) 0.86 (0.73–1.02) 0.08
* CABG denotes coronary-artery bypass grafting, and PCI percutaneous coronary intervention.
† The primary outcome was a composite of death, nonfatal stroke, nonfatal myocardial infarction, or new renal failure re-
quiring dialysis.
‡ All deaths in the first 30 days were considered to be cardiovascular-related deaths.
§ One patient underwent both CABG and PCI.
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Figure 2. Hazard Ratios for the Primary Outcome in Prespecified Subgroups.
Grades of 0 to 2 on the European System for Cardiac Operative Risk Evaluation (EuroSCORE) for CABG indicate low risk; 3 to 5, moderate 
risk; and more than 5, high risk. The body-mass index is the weight in kilograms divided by the square of the height in meters.
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Symbol Substitution Test, in the off-pump group 
than in the on-pump group at discharge (P = 0.04), 
but there was no significant between-group dif-
ference at 30 days or at 1 year. We found no dif-
ferences between the two groups in the change 
in scores on the Montreal Cognitive Assessment 
or the Trail Making Test Part B. Sensitivity analy-
ses comparing centers that had rates of participa-
tion in these assessments in the highest quartile 
with centers that had participation rates in the 
lower three quartiles also showed similar results 
(Table S4 in the Supplementary Appendix).
DISCUSSION
In this trial, we compared off-pump CABG with 
on-pump CABG in 4752 patients from 19 coun-
tries on five continents. We found no significant 
between-group difference at 1 year in the rate of 
the first coprimary outcome of death, nonfatal 
stroke, nonfatal myocardial infarction, or nonfa-
tal new renal failure requiring dialysis; in the rate 
of each component of the coprimary outcome; or 
in the rate of repeat revascularization. Although 
there was a small difference in cognitive func-
tion in favor of off-pump CABG at discharge, this 
benefit did not persist at 1 year.
Our results differ from those of the ROOBY 
trial.7,8 That trial showed a significantly higher 
rate of the composite outcome at 1 year with off-
pump CABG than with on-pump CABG (9.9% 
vs. 7.4%; relative risk, 1.33; 95% CI, 1.01 to 1.76; 
P = 0.04), whereas there was no significant dif-
ference in CORONARY. There are important differ-
ences between the two trials. CORONARY in-
cluded more than twice as many participants as 
were included in the ROOBY trial. In addition, the 
participants in our trial were enrolled at a diverse 
array of clinical settings, whereas the ROOBY 
trial recruited patients exclusively from the Vet-
erans Affairs system. We specified a higher level 
of surgical expertise at the beginning of the 
trial than was required in the ROOBY trial; each 
operation was performed by a surgeon who had 
more than 2 years of experience and had com-
pleted more than 100 cases of the specific tech-
nique (either on-pump or off-pump CABG) to be 
performed. In CORONARY, trainees were not 
allowed to be the primary surgeon. The rate of 
crossover from off-pump to on-pump CABG was 
lower in CORONARY than in the ROOBY trial 
(7.9% vs. 12.4%), and the rate of repeat revascu-
larization between 31 days and 1 year was also 
lower in CORONARY (0.7% in the off-pump group 
and 0.6% in the on-pump group vs. 4.6% and 
3.4%, respectively, in the ROOBY trial), suggest-
Table 2. Outcomes between 31 Days and 1 Year.*
Outcome
Off-Pump CABG
(N = 2142)
On-Pump CABG
(N = 2130)
Hazard Ratio
(95% CI) P Value
number (percent)
Primary outcome 55 (2.6) 69 (3.2) 0.79 (0.55–1.13) 0.19
Components of primary outcome
Death 44 (2.1) 50 (2.3) 0.87 (0.58–1.31)
Myocardial infarction 4 (0.2) 8 (0.4) 0.5 (0.15–1.65)
Stroke 10 (0.5) 12 (0.6) 0.83 (0.36–1.92)
New renal failure requiring dialysis 2 (0.1) 4 (0.2) 0.5 (0.09–2.71)
Other prespecified outcomes
Cardiovascular-related death 33 (1.5) 31 (1.5) 1.06 (0.65–1.73) 0.82
Angina 17 (0.8) 15 (0.7) 1.13 (0.56–2.26) 0.74
Repeat revascularization 16 (0.7) 13 (0.6) 1.22 (0.59–2.54) 0.59
PCI 15 (0.7) 13 (0.6) 1.15 (0.55–2.41) 0.72
CABG 1 (<0.1) 0 0.99
* The landmark analyses of data between 31 days and 1 year excluded data from patients who had a primary outcome in 
the first 30 days or who were not followed up after 30 days.
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Table 3. Quality of Life and Results of Neurocognitive Testing.*
Measure Off-Pump CABG On-Pump CABG P Value
No. of Patients Score No. of Patients Score
EQ-5D†
Baseline 1424 0.77±0.22 1421 0.77±0.22 0.97
Change from baseline
To discharge 1265 −0.03±0.28 1251 −0.03±0.26 0.75
To 30 days 1154 0.07±0.26 1161 0.08±0.25 0.25
To 1 year 1024 0.13±0.24 1035 0.14±0.24 0.25
EQ-5D visual-analogue scale‡
Baseline 1423 65.8±17.6 1422 66.6±17.8 0.24
Change from baseline
To discharge 1264 1.8±18.2 1250 1.0±17.8 0.26
To 30 days 1154 8.5±17.6 1159 8.0±17.6 0.44
To 1 year 1023 11.3±18.1 1035 11.4±17.6 0.88
Montreal Cognitive Assessment§
Baseline 1053 23.2±4.4 1028 23.2±4.3 0.90
Change from baseline
To discharge 896 0.2±2.9 881 0.1±2.9 0.22
To 30 days 797 1.0±3.1 784 0.8±3.1 0.26
To 1 year 645 0.4±4.0 628 0.3±4.0 0.51
Digit Symbol Substitution Test¶
Baseline 989 33.0±17.8 986 31.9±18.0 0.15
Change from baseline
To discharge 812 −1.6±11.4 797 −2.7±10.0 0.04
To 30 days 694 1.8±11.4 685 1.3±10.8 0.40
To 1 year 522 1.8±13.2 528 1.3±12.3 0.56
Trail Making Test Part B‖
Baseline 721 158.0±88.1 711 163.7±89.5 0.22
Change from baseline
To discharge 523 5.2±55.4 498 7.0±52.6 0.59
To 30 days 470 −10.9±58.1 487 −4.7±71.2 0.14
To 1 year 353 −6.8±64.0 340 −3.2±70.2 0.49
* Plus–minus values are means ±SD. The number of patients at baseline indicates the number of patients who completed 
the baseline test. The number of patients at a subsequent time indicates the number of patients who completed the test 
at baseline and at that specific time.
† The European Quality of Life–5 Dimensions (EQ-5D) questionnaire assesses five dimensions of quality of life. The total 
score ranges from 0 to 1, with higher scores indicating better quality-of-life status.
‡ The EQ-5D visual-analogue scale assesses the respondent’s self-rated health on a vertical, visual analogue scale. The 
total score ranges from 0 to 100, with higher scores indicating better health status.
§ The Montreal Cognitive Assessment assesses executive function and detects subtle memory impairment. The total 
score ranges from 0 to 30, with higher scores indicating better cognitive function.
¶ The Digit Symbol Substitution Test was designed to assess differences among cognitively intact persons in a wide array 
of cognitive domains such as visual-motor speed and coordination, capacity for learning, capacity for sustained effort, 
attention, concentration, ability to imitate newly learned visual material, and short-term memory. The lowest score is 0, and 
there is no upper limit; higher scores indicate better cognitive function.
‖ The Trail Making Test Part B is a test of scanning, visual-motor tracking, divided attention, and cognitive flexibility. The 
test is timed, and therefore a lower score (in seconds) indicates a better function.
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ing a higher level of surgical expertise in our 
trial. In both CORONARY and the ROOBY trial, 
the rates of the primary outcomes at 1 year 
among patients who underwent the assigned pro-
cedure (i.e., without crossing over to the other 
procedure) were consistent with those in the 
intention-to-treat analysis. In CORONARY, the 
rate of the primary end point was lower in the 
off-pump group than in the on-pump group 
(11.5% and 13.2%, respectively; P = 0.08), where-
as in the ROOBY trial, the rate was lower in the 
on-pump group (9.4% in the off-pump group vs. 
7.1% in the on-pump group; P = 0.08).
It is possible that the relative success of the 
two procedures is influenced by the risk level of 
the patients, since new techniques tend to show 
benefits in patients at higher surgical risk, who 
have more to gain with newer, less invasive tech-
niques.28,29 The participants in our trial were at 
a higher surgical risk than were patients in the 
ROOBY trial, as evidenced by the selection crite-
ria, the baseline characteristics, and the 30-day 
mortality. In the ROOBY trial, the 30-day mortal-
ity was 1.6% in the off-pump group and 1.2% in 
the on-pump group. In contrast, the 30-day mor-
tality in CORONARY was 2.5% in each group. 
The patients in CORONARY were older than 
were the patients in the ROOBY trial (mean age, 
67.5 years vs. 62.7 years), and more patients in 
CORONARY required emergency surgery (38.8% 
vs. 15.2%). Our trial also included a group of 
patients with more complex coronary anatomy. 
As compared with the ROOBY trial, CORONARY 
included more women (19.2% vs. 0.5%), more 
patients with left main coronary artery disease 
(21.5% vs. 0), and more patients with three-vessel 
disease (after exclusion of patients with left main 
coronary artery disease) (74.2% vs. 66.6%). In ad-
dition, 44% of the patients in CORONARY were 
of South Asian or East Asian ethnic groups, popu-
lations that are known to have smaller coronary 
arteries.30-32 Therefore the apparent differences in 
results between the ROOBY trial and CORONARY 
may be due to differences in the baseline risk of 
the patients as well as the differences in the 
experience levels of the surgeons.
Our trial has some limitations. The quality-of-
life and neurocognitive tests were optional, and 
some centers had low participation rates for these 
tests. We found that the patients who completed 
these tests were generally somewhat healthier than 
were patients who did not participate (Table S1 
in the Supplementary Appendix). In addition, 
among patients who agreed to participate, many, 
despite our best efforts, refused to complete the 
more demanding neurocognitive tests. These tests 
could also not be completed if the follow-up was 
conducted only by telephone. Patients who chose 
not to participate initially or who refused to 
participate later during the follow-up period may 
differ in some ways from those who did partici-
pate. Although the possibility of a bias in favor of 
a particular technique cannot be excluded, vari-
ous sensitivity analyses suggested that the results 
were robust and indicated little difference, if any, 
in quality of life or neurocognitive function be-
tween the patients in the two groups.
In conclusion, we conducted a large, random-
ized trial to compare the outcomes of on-pump 
CABG with off-pump CABG. At 1 year, we found 
no significant differences between the two groups 
in the rate of death, nonfatal stroke, nonfatal myo-
cardial infarction, or nonfatal new renal failure 
requiring dialysis or in the rate of subsequent 
revascularization procedures. We also found no 
significant differences in quality of life or in 
neurocognitive function.
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